Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 10:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inflammatory Lung Disease Clear all
Not listed Phase 2 Interventional

Biological Effects of Quercetin in COPD Phase II

NCT06003270
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Emphysema, Chronic Bronchitis With Airway Obstruction
Interventions
Quercetin 1000 mg, Quercetin 500 MG, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Jun 10, 2026, 10:11 PM EDT
Completed Phase 4 Interventional

Sleep Intervention During Acute Lung Injury

NCT01050699
View directory record Official record
Conditions
Critical Illness, Sleep, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Dexmedetomidine, Midazolam and Fentanyl
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Jun 10, 2026, 10:11 PM EDT
Completed No phase listed Observational

Optimizing Clinical Use of Polymyxin B

NCT02682355
View directory record Official record
Conditions
Pneumonia, Blood Stream Infection, Urinary Tract Infections, Respiratory Tract Infection (Including Tracheobronchitis), Sepsis
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2024 · Synced Jun 10, 2026, 10:11 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of IV ST266 in COVID-19 Subjects

NCT04720378
View directory record Official record
Conditions
Cytokine Release Syndrome
Interventions
ST266
Biological
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Clearwater, Florida • Chicago, Illinois • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Jun 10, 2026, 10:11 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prognostic Indicators as Provided by the EPIC ClearView

NCT01476995
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2011 · Synced Jun 10, 2026, 10:11 PM EDT
Enrolling by invitation No phase listed Observational

Evaluating the Response of the Immune System of People with Long COVID (post SARS-CoV-2)

NCT05131594
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Huntington Memorial Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 10, 2026, 10:11 PM EDT
Terminated Phase 2 Interventional Results available

COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes

NCT04537299
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Fisetin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Jun 10, 2026, 10:11 PM EDT
Terminated Phase 2 Interventional Results available

Etoposide in Patients With COVID-19 Infection

NCT04356690
View directory record Official record
Conditions
COVID-19
Interventions
Etoposide
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jun 10, 2026, 10:11 PM EDT
Not listed Phase 2 Interventional

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.

NCT04869579
View directory record Official record
Conditions
Covid19
Interventions
Selenium (as Selenious Acid), Placebo
Drug · Other
Lead sponsor
CHRISTUS Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Longview, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Jun 10, 2026, 10:11 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Pulmonary and Inflammatory Responses Following Exposure to a Low Concentration of Ozone or Clean Air at Rest

NCT06943989
View directory record Official record
Conditions
Lung Inflammation, Experimental Lung Inflammation
Interventions
Ozone Exposure, Clean air (0.0 ppm ozone)
Other
Lead sponsor
Environmental Protection Agency (EPA)
Federal
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Jun 10, 2026, 10:11 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome

NCT04540120
View directory record Official record
Conditions
Covid19, Cytokine Release Syndrome
Interventions
dapansutrile capsules, placebo capsules
Drug
Lead sponsor
Olatec Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Coral Gables, Florida • Fort Lauderdale, Florida • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Jun 10, 2026, 10:11 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sickle Cell Pro-Inflammatory Response to Interval Training Study

NCT03653676
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Exercise Test (CIIT)
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
10 Years to 21 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Jun 10, 2026, 10:11 PM EDT
Terminated Phase 3 Interventional

Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure

NCT00016523
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Respiratory Distress Syndrome (RDS), Sepsis, Pneumonia, Hypertension, Pulmonary
Interventions
Inhaled nitric oxide, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 120 Hours
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Jun 10, 2026, 10:11 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

NCT06665256
View directory record Official record
Conditions
Idiopathic Inflammatory Myopathies
Interventions
Rapcabtagene autoleucel, Active Comparator Option
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
9
States / cities
Birmingham, Alabama • Zephyrhills, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 10, 2026, 10:11 PM EDT
Completed Phase 2 Interventional

Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome

NCT00879606
View directory record Official record
Conditions
Sepsis, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
ALT-836, Placebo
Drug
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
20
States / cities
Los Angeles, California • Sacramento, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Jun 10, 2026, 10:11 PM EDT
Not listed No phase listed Observational

SQuISH-COVID: A Pilot Study

NCT04372472
View directory record Official record
Conditions
Sepsis, COVID-19
Interventions
Not listed
Lead sponsor
Cytovale, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Jun 10, 2026, 10:11 PM EDT
Terminated Phase 3 Interventional

A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)

NCT04636814
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
CHF6001 1600µg, CHF6001 3200µg, Placebo, Roflumilast
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
40 Years and older
Enrollment
3,973 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
150
States / cities
Andalusia, Alabama • Foley, Alabama • Guntersville, Alabama + 102 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jun 10, 2026, 10:11 PM EDT
Completed No phase listed Observational

Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19

NCT04706533
View directory record Official record
Conditions
Covid19, Kidney Diseases, Inflammation, SARS-CoV Infection
Interventions
Biomarkers of inflammation
Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
3,402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Jun 10, 2026, 10:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Plastic Hat Trial to Prevent Hypothermia in Preterm Newborns in the Delivery Room

NCT00904228
View directory record Official record
Conditions
Hypothermia
Interventions
placement of plastic cap during delivery room stabilization, placement of routine cap during delivery room stabilization
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 1 Hour
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Jun 10, 2026, 10:11 PM EDT
Completed Phase 2 Interventional

Steroids and Methotrexate to Treat Systemic Vasculitis

NCT00001256
View directory record Official record
Conditions
Inflammation, Vasculitis, Wegener's Granulomatosis
Interventions
prednisone and methotrexate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 10:11 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pathogenesis and Genetics of Environmental Asthma Ozone Study

NCT00574158
View directory record Official record
Conditions
Asthma, Inflammation
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 35 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2014 · Synced Jun 10, 2026, 10:11 PM EDT
Withdrawn Phase 2 Interventional

Anti-Inflammatory Lipid Mediators in Asthma

NCT03680976
View directory record Official record
Conditions
Asthma
Interventions
CXA-10, Placebo
Drug
Lead sponsor
Sally E. Wenzel MD
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Jun 10, 2026, 10:11 PM EDT
Completed No phase listed Observational

Exhaled Breath Condensate as a Measure of Airway Inflammation in Children With Asthma

NCT00078208
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 17 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 10:11 PM EDT
Terminated No phase listed Observational

Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies

NCT03557749
View directory record Official record
Conditions
Immune and Microbial Reconstitution, Systemic Viral Infection, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease, Recurrent Malignancy, Cytokine Release Syndrome, Allogenic Related Donors, Cell Therapy/Immunotherapy Patients
Interventions
Blood Sample, Stool Sample, Urine Sample, Bronchoalveolar Lavage (BAL) fluid, Gastrointestinal biopsy x 2-4, Skin biopsy, Skin, mouth, and/or ocular swab, Apheresis Product, Final cellular product
Diagnostic Test
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jun 10, 2026, 10:11 PM EDT